Publicaciones en las que colabora con Ovidio Muñiz Grijalvo (16)

2024

  1. Age- and sex-based heterogeneity in coronary artery plaque presence and burden in familial hypercholesterolemia: A multi-national study

    American Journal of Preventive Cardiology, Vol. 17

  2. Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia: a worldwide cross-sectional study

    The Lancet Diabetes and Endocrinology, Vol. 12, Núm. 11, pp. 811-823

  3. Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study

    Circulation. Cardiovascular imaging, Vol. 17, Núm. 1, pp. e016206

  4. Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study

    The Lancet Diabetes and Endocrinology, Vol. 12, Núm. 9, pp. 643-652

2023

  1. Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study

    Circulation, Vol. 147, Núm. 19, pp. 1436-1443

  2. Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study

    European journal of preventive cardiology, Vol. 30, Núm. 4, pp. 320-328

2022

  1. A resilient type of familial hypercholesterolaemia: case-control follow-up of genetically characterized older patients in the SAFEHEART cohort

    European Journal of Preventive Cardiology, Vol. 29, Núm. 5, pp. 795-801

  2. Predicting resilience in heterozygous familial hypercholesterolaemia: A cohort study of octogenarian patients

    Journal of Clinical Lipidology, Vol. 16, Núm. 5, pp. 733-736

2021

  1. Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: A computed tomographic angiography study

    Atherosclerosis, Vol. 317, pp. 52-58

  2. Lipoprotein(a), LDL-cholesterol, and hypertension: Predictors of the need for aortic valve replacement in familial hypercholesterolaemia

    European Heart Journal, Vol. 42, Núm. 22, pp. 2201-2211

  3. The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia

    JACC: Cardiovascular Imaging, Vol. 14, Núm. 12, pp. 2414-2424

2020

  1. Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry

    Revista Espanola de Cardiologia, Vol. 73, Núm. 10, pp. 828-834

2019

  1. Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study

    Journal of Clinical Lipidology, Vol. 13, Núm. 6, pp. 989-996

  2. Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia

    Atherosclerosis, Vol. 286, pp. 40-45

  3. VEGFR2 and OPG genes modify the risk of subclinical coronary atherosclerosis in patients with familial hypercholesterolemia

    Atherosclerosis, Vol. 285, pp. 17-22

2018

  1. Coronary computed tomographic angiography findings and their therapeutic implications in asymptomatic patients with familial hypercholesterolemia. Lessons from the SAFEHEART study

    Journal of Clinical Lipidology, Vol. 12, Núm. 4, pp. 948-957